Cromolyn sodium - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for cromolyn sodium and what is the scope of patent protection?
Cromolyn sodium
is the generic ingredient in seven branded drugs marketed by King Pharms Llc, Sanofi Aventis Us, Ucb Inc, Ailex Pharms Llc, Genera Pharms, Micro Labs Ltd India, Rising, Mylan Speciality Lp, Bausch And Lomb, Apotex Inc, Sandoz, Sciegen Pharms Inc, King Pharms, Allergan, Actavis Mid Atlantic, Bausch, Eugia Pharma, Hikma, Micro Labs, Roxane, Teva Pharms, Virtus, Watson Labs, Wockhardt Bio Ag, Hh And P, Perrigo, and Blacksmith Brands, and is included in thirty-one NDAs. Additional information is available in the individual branded drug profile pages.There are ten drug master file entries for cromolyn sodium. Eighteen suppliers are listed for this compound.
Summary for cromolyn sodium
US Patents: | 0 |
Tradenames: | 7 |
Applicants: | 27 |
NDAs: | 31 |
Drug Master File Entries: | 10 |
Finished Product Suppliers / Packagers: | 18 |
Raw Ingredient (Bulk) Api Vendors: | 76 |
Clinical Trials: | 23 |
Patent Applications: | 8,076 |
What excipients (inactive ingredients) are in cromolyn sodium? | cromolyn sodium excipients list |
DailyMed Link: | cromolyn sodium at DailyMed |
Recent Clinical Trials for cromolyn sodium
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Texas Tech University Health Sciences Center, El Paso | Phase 3 |
Adli Karadsheh, MD, MS | Phase 3 |
Pharma Consulting Group (PCG) | Phase 2 |
Pharmacology for cromolyn sodium
Drug Class | Mast Cell Stabilizer |
Physiological Effect | Decreased Histamine Release |
Medical Subject Heading (MeSH) Categories for cromolyn sodium
US Patents and Regulatory Information for cromolyn sodium
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Actavis Mid Atlantic | CROMOLYN SODIUM | cromolyn sodium | SOLUTION;INHALATION | 075067-001 | Jul 19, 1999 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
Allergan | OPTICROM | cromolyn sodium | SOLUTION/DROPS;OPHTHALMIC | 018155-001 | Oct 3, 1984 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
Ailex Pharms Llc | CROMOLYN SODIUM | cromolyn sodium | CONCENTRATE;ORAL | 209264-001 | Oct 16, 2017 | AA | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for cromolyn sodium
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Sanofi Aventis Us | INTAL | cromolyn sodium | CAPSULE;INHALATION | 016990-001 | Approved Prior to Jan 1, 1982 | ⤷ Subscribe | ⤷ Subscribe |
Allergan | OPTICROM | cromolyn sodium | SOLUTION/DROPS;OPHTHALMIC | 018155-001 | Oct 3, 1984 | ⤷ Subscribe | ⤷ Subscribe |
King Pharms Llc | INTAL | cromolyn sodium | SOLUTION;INHALATION | 018596-001 | May 28, 1982 | ⤷ Subscribe | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Cromolyn sodium Market Analysis and Financial Projection Experimental
More… ↓
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.